Neuroblastoma Clinical Trials in Austin, Texas

5 studies are recruiting for neuroblastoma in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

    This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuxima…

    Stage
    Phase 3
    Ages
    Up to 30
    Site
    Dell Children's Medical Center of Central Texas, Austin, Texas
    Locations
    179 in total
    Run by
    National Cancer Institute (NCI)
  2. Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Newly Diagnos…

    Stage
    Phase 2
    Ages
    Up to 22
    Site
    Dell Children's Blood and Cancer Center, Austin, Texas
    Locations
    28 in total
    Run by
    Giselle Sholler
  3. Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

    The purpose of this study is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the Food and Drug Administration (FDA) approved drug, naxitimab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been pla…

    Stage
    Phase 2
    Ages
    1 to 21
    Site
    Dell Children's Blood and Cancer Center, Austin, Texas
    Locations
    12 in total
    Run by
    Giselle Sholler
  4. Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

    This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lor…

    Stage
    Phase 3
    Ages
    1 to 30
    Site
    Dell Children's Medical Center of Central Texas, Austin, Texas
    Locations
    164 in total
    Run by
    Children's Oncology Group
  5. Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

    This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be ad…

    Stage
    Phase 2
    Ages
    1 to 21
    Site
    Dell Children's Blood and Cancer Center, Austin, Texas
    Locations
    26 in total
    Run by
    Giselle Sholler

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.